1
Clinical Trials associated with Universal Dual-target NKG2D-NKp44 CAR-T Cells(Zhejiang University)A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacodynamics and Immunogenicity of Universal CNK-UT Cells in Patients With Advanced Solid Tumors.
This is a single arm, open-label, multi-center, phase I study to evaluate the safety, tolerability, preliminary efficacy, pharmacodynamics and immunogenicity of universal chimeric natural killer receptor modified T-cells (CNK-UT) targeting NKG2D-Ligands and NCR2-Ligands with or without lymphodepletion in advanced solid tumors.
100 Clinical Results associated with Universal Dual-target NKG2D-NKp44 CAR-T Cells(Zhejiang University)
100 Translational Medicine associated with Universal Dual-target NKG2D-NKp44 CAR-T Cells(Zhejiang University)
100 Patents (Medical) associated with Universal Dual-target NKG2D-NKp44 CAR-T Cells(Zhejiang University)
100 Deals associated with Universal Dual-target NKG2D-NKp44 CAR-T Cells(Zhejiang University)